Edimer is a privately held biotechnology company based in Cambridge, Massachusetts dedicated to delivering a significant and durable improvement in the health and quality of life for future generations affected by the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). Edimer was established in 2009.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/30/13 | $18,000,000 | Series B |
Sanofi-Genzyme BioVentures VI Partners | undisclosed |
